Milligest (Ethinylestradiol, Gestodene)

Ethinylestradiol, the active ingredient in Milligest, is a combined oral contraceptive presented as an oral tablet for oral use. Together with gestodene, it provides hormonal regulation to inhibit ovulation and prevent pregnancy in women of reproductive age, offering a reliable method of contraception.

GNH USA supplies Milligest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance for global distribution. The company adheres to stringent manufacturing standards and provides reliable logistics support for timely delivery to healthcare providers.

Milligest, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy. - Contraception: Prevents pregnancy by suppressing ovulation. - Menstrual cycle regulation: Helps achieve more regular menstrual bleeding. - Acne management: Reduces androgen‑driven acne in women.

Oral administration of Milligest may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of breast tissue. - Spotting: irregular light bleeding between periods. - Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: neurological events due to clot formation. - Myocardial infarction: heart attack risk, especially in smokers over 35. - Severe hypertension: sudden increase in blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Milligest, clinicians should evaluate individual risk factors and contraindications. - Assess cardiovascular risk: review history of thromboembolic events or clotting disorders. - Screen smoking status: avoid use in women over 35 who smoke. - Review hepatic function: contraindicated in severe liver disease. - Consider drug interactions: avoid concomitant use with potent enzyme inducers. - Pregnancy category: contraindicated in pregnancy; advise effective backup contraception. - Store at ambient temperature: keep tablets in the original pack, protect from moisture and light.

Milligest can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): reduce contraceptive effectiveness. - Rifampin: decreases hormone levels, increasing risk of unintended pregnancy. - St. John’s wort: may diminish contraceptive effect through hepatic enzyme induction.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk. - Certain antibiotics (e.g., tetracycline): potential modest reduction in contraceptive efficacy. - SSRIs (e.g., fluoxetine): may increase bleeding tendency when combined with hormonal therapy.